


Journal Pre-proof

WITHDRAWN: Development of the SMA Independence Scale–Upper Limb Module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA

Dylan Trundell, Anne Skalicky, Hannah Staunton, Asha Hareendran, Stephanie Le Scouiller, Louise Barrett, Owen Cooper, Ksenija Gorni, Tim Seabrook, Sangeeta Jethwa, Stefan Cano



PII: S0022-510X(21)00011-3

DOI: <https://doi.org/10.1016/j.jns.2021.117318>

Reference: JNS 117318

To appear in: *Journal of the Neurological Sciences*

Please cite this article as: D. Trundell, A. Skalicky, H. Staunton, et al., WITHDRAWN: Development of the SMA Independence Scale–Upper Limb Module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA, *Journal of the Neurological Sciences* (2021), <https://doi.org/10.1016/j.jns.2021.117318>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021

WITHDRAWN: Development of the SMA Independence Scale—
Upper Limb Module (SMAIS—ULM): A novel scale for
individuals with Type 2 and non-ambulant Type 3 SMA

Dylan Trundell^{a,*} dylan.trundell@roche.com, Anne Skalicky^b
anne.skalicky@evidera.com, Hannah Staunton^a hannah.staunton@roche.com,
Asha Hareendran^c asha.hareendran@evidera.com, Stephanie Le Scouiller^a
stephanie.le_scouiller@roche.com, Louise Barrett^d
louise.barrett@modusoutcomes.com, Owen Cooper^c
owen.cooper@evidera.com, Ksenija Gorni^c ksenija.gorni@roche.com, Tim
Seabrook^f seabrooktim@hotmail.com, Sangeeta Jethwa^f
sangeeta.jethwa@gmail.com, Stefan Cano^d stefan.cano@modusoutcomes.com

^a*Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7
1TW, UK*

^b*Evidera, Broderick Building, 515 2nd Ave., Suite 500, Seattle, WA 98104, USA*

^c*Evidera, The Ark, 201 Taggerlin Rd, Hammersmith, London W6 8BJ, UK*

^d*Modus Outcomes, Suite 210b, Spirella Building, Letchworth Garden City, SG6 4ET UK*

^e*PDMA, Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland*

^f*Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel,
Basel, Switzerland*

^{*}*Corresponding author at: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park,
Welwyn Garden City, AL7 1TW, United Kingdom*

This article has been withdrawn at the request of the author(s)/Editor. The
Publisher apologizes for any inconvenience this may cause.

The full Elsevier Policy on Article Withdrawal can be found at
<https://www.elsevier.com/about/our-business/policies/article-withdrawal>